Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

BACKGROUND: Multiple sclerosis (MS) negatively affects health-related quality of life (HRQoL). OBJECTIVE: To evaluate HRQoL in people with highly active relapsing MS treated with cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) in CLARIFY-MS. METHODS: Changes in the MS quality of l...

Descripción completa

Detalles Bibliográficos
Autores principales: Brochet, Bruno, Solari, Alessandra, Lechner-Scott, Jeannette, Piehl, Fredrik, Langdon, Dawn, Hupperts, Raymond, Selmaj, Krzysztof, Patti, Francesco, Brieva, Luis, Maida, Eva Maria, Alexandri, Nektaria, Smyk, Andrzej, Nolting, Axel, Keller, Birgit, Montalban, Xavier, Kubala Havrdova, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687821/
https://www.ncbi.nlm.nih.gov/pubmed/37978852
http://dx.doi.org/10.1177/13524585231205962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687821/
https://www.ncbi.nlm.nih.gov/pubmed/37978852
http://dx.doi.org/10.1177/13524585231205962

Ejemplares similares